{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:51:59Z","timestamp":1777553519968,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016319","name":"China National Biotec Group Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.02.073","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:53:59Z","timestamp":1617188039000},"page":"2467-2474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement"],"prefix":"10.1016","volume":"39","author":[{"given":"Haiping","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-4355","authenticated-orcid":false,"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.073_b0005","unstructured":"Hamborsky J, Kroger A, Wolfe C, Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) (13th edition) April, 2015."},{"key":"10.1016\/j.vaccine.2021.02.073_b0010","unstructured":"Global Wild Poliovirus 2014\u20132019 Data from World Health Organization (WHO) HQ as of 29 Jan. 2019."},{"key":"10.1016\/j.vaccine.2021.02.073_b0015","unstructured":"Does polio still exist? Is it curable?. World Health Organization (WHO). Retrieved 21 May 2018."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2021.02.073_b0020","first-page":"S431","article-title":"Immunization with oral poliovirus vaccine in China","volume":"6","author":"Dong","year":"1984","journal-title":"Rev Infect Dis."},{"issue":"42","key":"10.1016\/j.vaccine.2021.02.073_b0025","first-page":"941","article-title":"Polio-free certification and lessons learned\u2013South-East Asia region, March 2014","volume":"63","author":"Bahl","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9","key":"10.1016\/j.vaccine.2021.02.073_b0030","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/JCM.00712-10","article-title":"Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi China","volume":"48","author":"Yan","year":"2010","journal-title":"J. Clinical Microbiology."},{"key":"10.1016\/j.vaccine.2021.02.073_b0035","doi-asserted-by":"crossref","unstructured":"Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 296 (5566): 356-59.","DOI":"10.1126\/science.1068284"},{"key":"10.1016\/j.vaccine.2021.02.073_b0040","unstructured":"Polio vaccines: WHO position paper. World Health Organization (March 2016). Weekly Epidemiological Record. 91 (12): 145\u201368."},{"key":"10.1016\/j.vaccine.2021.02.073_b0045","unstructured":"Poliomyelitis. World Health Organization (WHO). Retrieved 25 April 2017."},{"key":"10.1016\/j.vaccine.2021.02.073_b0050","unstructured":"Replacing trivalent OPV with bivalent OPV. World Health Organization (WHO). Retrieved 30 May 2019."},{"issue":"9","key":"10.1016\/j.vaccine.2021.02.073_b0055","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.02.073_b0060","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O'Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10011","key":"10.1016\/j.vaccine.2021.02.073_b0065","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.073_b0070","unstructured":"Guiding principles for classification criteria of adverse events in vaccine clinical trials. China's National Medical Products Administration 2005 Edition"},{"key":"10.1016\/j.vaccine.2021.02.073_b0075","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 \u2013 conclusions and recommendations. Wkly Epidemiol Rec 2013;88:1\u201316."},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.073_b0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14760584.8.1.5","article-title":"Role of injectable and oral polio vaccines in polio eradication","volume":"8","author":"John","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"10.1016\/j.vaccine.2021.02.073_b0085","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.02.073_b0090","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/14760584.2016.1158650","article-title":"Alternative administration routes and delivery technologies for polio vaccines","volume":"15","author":"Kraan","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2021.02.073_b0095","first-page":"237","article-title":"Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities \u2013 Kenya, December 2013","volume":"63","author":"Sheikh","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2021.02.073_b0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.073_b0105","doi-asserted-by":"crossref","unstructured":"WHO. Polio vaccines: WHO position paper, January 2014\u2014recommendations. Vaccine 2014; 32: 4117\u201318.","DOI":"10.1016\/j.vaccine.2014.04.023"},{"key":"10.1016\/j.vaccine.2021.02.073_b0110","doi-asserted-by":"crossref","unstructured":"Ciapponi A, Bardach A, Rey Ares L, et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst Rev. 2019;12(12):CD011260. Published 2019 Dec 5. doi:10.1002\/14651858.CD011260.pub2","DOI":"10.1002\/14651858.CD011260.pub2"},{"key":"10.1016\/j.vaccine.2021.02.073_b0115","doi-asserted-by":"crossref","unstructured":"O'Ryan M, Bandyopadhyay AS, Villena R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study [published correction appears in Lancet Infect Dis. 2015 Oct;15(10):1130]. Lancet Infect Dis. 2015;15(11):1273-1282. doi:10.1016\/S1473-3099(15)00219-4","DOI":"10.1016\/S1473-3099(15)00219-4"},{"key":"10.1016\/j.vaccine.2021.02.073_b0120","doi-asserted-by":"crossref","unstructured":"Yan S, Chen H, Zhang Z, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China Vaccine. 2020;S0264-410X(20)30971-3. doi:10.1016\/j.vaccine.2020.07.042","DOI":"10.1016\/j.vaccine.2020.07.042"},{"issue":"03","key":"10.1016\/j.vaccine.2021.02.073_b0125","first-page":"265","article-title":"Immunogenicity of two sequential primary immunization schedules with inactivated poliovirus vaccine and bivalent oral poliomyelitis attenuated live vaccine","volume":"26","author":"Zhang","year":"2020","journal-title":"Chinese Journal Of Vaccines And Immunization."},{"key":"10.1016\/j.vaccine.2021.02.073_b0130","doi-asserted-by":"crossref","unstructured":"Bakker WA, Thomassen YE, van't Oever AG, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29(41):7188-7196. doi:10.1016\/j.vaccine.2011.05.079","DOI":"10.1016\/j.vaccine.2011.05.079"},{"key":"10.1016\/j.vaccine.2021.02.073_b0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trivac.2015.08.001","article-title":"Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies","volume":"4","author":"Resik","year":"2015","journal-title":"Trials Vaccinol."},{"issue":"11","key":"10.1016\/j.vaccine.2021.02.073_b0140","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis."},{"issue":"2","key":"10.1016\/j.vaccine.2021.02.073_b0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis."},{"issue":"42","key":"10.1016\/j.vaccine.2021.02.073_b0150","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.02.073_b0155","unstructured":"Fu Simei, Lin Lin, Cao Fengrui, et al.Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province. Chinese Journal Vaccines And Immunization,2017,23(04):379-382+374."},{"key":"10.1016\/j.vaccine.2021.02.073_b0160","unstructured":"WHO. 2015. WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:55:38Z","timestamp":1759402538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21002644"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}